U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. Recent deals could be worth ...

How pharmaceutical tariffs could reshape drug pricing, supply chains and domestic production in the United States, according ...

America's pharmaceutical sector is facing huge uncertainty from the tariff threat, cuts at the US Department of Health, and a ...

Trump and his aides have repeatedly shifted their stance on tariffs in the weeks since the president’s “Liberation Day” ...

US President Donald Trump on May 23 threatened to impose a 50 percent tariff on all imports from the European Union.

So far, China has made no official public threat about weaponizing its dominant position in this segment of the ...

U.S. dependency on China for critical goods like rare earths and pharmaceuticals poses risks. Trump's strategies aim to ...

The United States Court of Appeals for the Federal Circuit consolidated and temporarily stayed the first decision from the ...

Volley after volley of new tariffs from U.S. President Donald Trump have plunged the country into trade wars abroad, creating ...

The U.S. federal court ruling that President Trump had overstepped his authority on imposing tariffs marked a clear setback ...

US President Donald Trump’s tariff decisions since he took office on Jan 20 have given investors and political leaders alike ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...